Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus FULVICIN P G.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus FULVICIN P G.
EXTINA vs FULVICIN P/G
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Binds to microtubule-associated proteins, disrupting mitotic spindle formation and inhibiting fungal cell division.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
250 mg orally twice daily for tinea infections; 500 mg orally twice daily for onychomycosis. Administer with a fatty meal to enhance absorption.
None Documented
None Documented
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
Terminal elimination half-life: 9–24 hours (mean ~16 hours). Clinical context: prolonged half-life allows once-daily dosing; steady-state achieved within 2–3 days.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Renal (largely unchanged, <1% as metabolites); biliary/fecal (minor). Approximately 36% of a dose is excreted in urine within 6 hours, and up to 50% within 72 hours.
Category C
Category C
Antifungal
Antifungal